Evaluation of Microglial Activation in Multiple Sclerosis Patients Using Positron Emission Tomography
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Understanding the mechanisms underlying progression in multiple sclerosis (MS) is one of the key elements contributing to the identification of appropriate therapeutic targets for this under-managed condition. In addition to plaque-related focal inflammatory pathology typical for relapsing remitting MS there are, in progressive MS, widespread diffuse alterations in brain areas outside the focal lesions. This diffuse pathology is tightly related to microglial activation and is co-localized with signs of neurodegeneration. Microglia are brain resident cells of the innate immune system and overactivation of microglia is associated with several neurodegenerative diseases. Understanding the role of microglial activation in relation to developing neurodegeneration and disease progression may provide a key to developing therapies to target progressive MS. 18 kDa translocator protein (TSPO) is a mitochondrial molecule upregulated in microglia upon their activation. Positron emission tomography (PET) imaging using TSPO-binding radioligands provides a method to assess microglial activation in patients in vivo. In this mini-review, we summarize the current status of TSPO imaging in the field of MS. In addition, the review discusses new insights into the potential use of this method in treatment trials and in clinical assessment of progressive MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905 · cited 10×
“(11)C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease.”
BackgroundMethodInfluentialThe relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Owen, D. R., Yeo, A. J., Gunn, R. N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C., Pulford, D. J., Bennacef, I., Parker, C. A., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.147 · Cited by 779
Fischer, M. T., Sharma, R., Lim, J. L., Haider, L., Frischer, J. M., Drexhage, J., Mahad, D., Bradl, M., van Horssen, J., & Lassmann, H. (2012) · Brain · doi:10.1093/brain/aws012 · Cited by 507
Nylander, A., & Hafler, D. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58649 · Cited by 495
Cosenza‐Nashat, M., Zhao, M. ‐., Suh, H. ‐., Morgan, J., Natividad, R., Morgello, S., & Lee, S. C. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.01006.x · Cited by 459 · cited 1×
“Neuropathological studies of TSPO localization in various types and various patho-anatomical locations in MS brain tissue in situ are, unfortunately, still relatively limited (21).”
BackgroundMultiple sclerosis normal‐appearing white matter: Pathology–imaging correlations
Moll, N. M., Rietsch, A. M., Thomas, S., Ransohoff, A. J., Lee, J., Fox, R., Chang, A., Ransohoff, R. M., & Fisher, E. (2011) · Annals of Neurology · doi:10.1002/ana.22521 · Cited by 297
Positron emission tomography and functional characterization of a complete PBR/TSPO knockout
Banati, R. B., Middleton, R. J., Chan, R., Hatty, C. R., Wai-Ying Kam, W., Quin, C., Graeber, M. B., Parmar, A., Zahra, D., Callaghan, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6452 · Cited by 241
Cited by
Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology
Voet, S., Prinz, M., & van Loo, G. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.005 · Cited by 503
Microglia in multiple sclerosis: Friend or foe
Guerrero, B. L., & Sicotte, N. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00374 · Cited by 215
“Translocator Protein (TSPO) is located in the outer mitochondrial membrane and is upregulated in activated microglia (46, 47).”
BackgroundInfluentialMechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis
Correale, J., Marrodan, M., & Ysrraelit, M. C. (2019) · Biomedicines · doi:10.3390/biomedicines7010014 · Cited by 167
Exploring Sex-Related Differences in Microglia May Be a Game-Changer in Precision Medicine
Lynch, M. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.868448 · Cited by 146
“Several diseases are marked by differences in incidence, symptoms and progression between males and females and sex is an acknowledged risk factor in diseases that are characterized by neuroinflammation, including autism spectrum disorders (ASD) Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis an…”
BackgroundMicroglia in multiple sclerosis - pathogenesis and imaging
Airas, L., & Yong, V. W. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001045 · Cited by 52
Self-citation
Metadata
- Authors
- Airas, L., Nylund, M., & Rissanen, E.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-26
- Volume
- 9
- Pages
- 181-181
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2793209973
- Cited by
- 71
- References
- 21
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Microglial Activation in Multiple Sclerosis Patients Using Positron Emission Tomography. https://app.cochat.ai/papers/10.3389/fneur.2018.00181
- The paper
- Airas, L., Nylund, M., & Rissanen, E. (2018). Evaluation of Microglial Activation in Multiple Sclerosis Patients Using Positron Emission Tomography. Frontiers in Neurology. https://doi.org/10.3389/fneur.2018.00181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.